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Abstract
Background: A majority of women from all cultures and socioeconomic levels experience diverse
psychosomatic and behavioral symptoms premenstrually, a phenomenon commonly termed premenstrual
syndrome, although symptoms and discomfort levels vary from woman to woman. The underlying
pathological mechanisms of premenstrual syndrome remain unknown; however, altered function or even
slight disorder of the blood circulation system, which contributes to the orchestrations of the human
internal environment, could cause bio-psychological changes leading to complaints and ultimately
compromising a woman's overall health. The present study, therefore, investigates to what extent and how
the menstrual cyclicity of peripheral circulation is associated with premenstrual symptomatology.
Methods:  Twenty-one eumenorrheic young women participated in this study. All subjects were
investigated during the follicular and late luteal phases. Cycle phase was determined by the onset of
menstruation and oral temperature and was verified by concentrations of ovarian hormones, estrone, and
pregnanediol in a urine sample taken early in the morning. Peripheral circulation was evaluated with the
Astrim (Sysmex, Kobe), a portable non-invasive monitoring device using the principle of near-infrared
spectroscopy, which calculates the venous oxygenation index (VOI) based on the ratio of light absorption
of oxyhemoglobin and deoxyhemoglobin, a proven reliable indicator of peripheral blood circulation. The
Menstrual Distress Questionnaire was applied to measure physical, emotional, and behavioral symptoms
accompanying the menstrual cycle of the subjects.
Results:  The oral temperature and urinary ovarian hormones adjusted for creatinine significantly
increased in the late luteal phase in all subjects. While 10 subjects experienced no symptoms during the
menstrual cycle, 11 subjects had apparent physical and psychological discomfort in the late luteal phase.
We found that VOI decreased more significantly in the late luteal phase than in the follicular phase only in
women with premenstrual discomfort although the symptoms were not unbearable enough to cause the
disruption of daily activities.
Conclusion: Several models have tried to explain the etiopathogenesis of premenstrual syndrome.
Although causes and consequences remain enigmatic, our data suggest that the peripheral circulation could
alter in the luteal phase, which might be partly associated with premenstrual psychosomatic symptoms in
eumenorrheic young women.
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Background
Women of reproductive age have a circumlunar rhythm or
a monthly cycle of the reproductive system, involving
gonadotropin, ovarian hormones, and basal body tem-
perature. During the late luteal phase, not all but a major-
ity of women from all cultures and socioeconomic levels
experience a cacophony of mind and body, that is, a regu-
lar recurrence of diverse physiological, psychological,
and/or behavioral symptoms to varying degrees, which
abates shortly after the onset of menstruation [1,2]. Over
150 complaints have been reported, and cardinal symp-
toms include: cramps, breast tenderness, swelling of
extremities, irritability, depression, headaches, and food
cravings [3]. This cluster of symptoms has become known
as premenstrual syndrome.
Interestingly, physicians in the East have recognized pre-
menstrual disorders for centuries. In the early third cen-
tury, the oldest Chinese practical medical textbook, Shang
han lun (Figure 1), describes premenstrual disorders:
"Women appear to have unusual conditions in the pre-
menstrual phase while experiencing various psychoso-
matic symptoms including lower abdominal bloating and
discomforts, which might be caused by 'oketsu' (blood
stagnation) syndrome. However, they get over the symp-
toms after bleeding." In addition, tokaku-joki-to (tao-he-
cheng-qi-tang), a type of Kampo medicine for overcoming
blood stagnation or stasis, was recommended to treat pre-
menstrual discomfort [4].
Peripheral blood circulation in capillary vessels, which
account for up to 90% of total blood vessels in the body,
plays a crucial role in maintaining homeostasis in the
human internal environment. Thus, altered function or
even slight disorder of the peripheral circulation system
could induce bio-psychological changes leading to com-
plaints and ultimately undermining overall health.
Although the etiopathogenesis of premenstrual syndrome
has been extensively studied [5], a paucity of information
is available regarding a potential association of peripheral
blood circulation and broadly ranged psychosomatic phe-
nomena in the late luteal phase.
The Astrim (Sysmex, Kobe), a portable non-invasive mon-
itoring device, determines hemoglobin levels by using the
principle of near-infrared spectroscopy [6-8]. The device
calculates the venous oxygenation index (VOI) based on
the ratio of light absorption of oxyhemoglobin (HbO2)
and deoxyhemoglobin (Hb). Previous studies have
shown that the VOI serves as a potential indicator in eval-
uating peripheral venous oxygen metabolism and skin
blood flow under different physiological circumstances
[9,10]. The non-invasive portable monitoring device has
several advantages, especially for clinical science research
fields. It could periodically and/or constantly observe bio-
logical changes in peripheral circulation during an exper-
iment and/or a treatment without burden or pain on
subjects.
Accordingly, the present study was designed to investigate
whether the VOI, an index for peripheral blood circula-
tion, changes during the menstrual cycle in eumenorrheic
young women. We further scrutinized the extent to which
and the manner in which the menstrual cyclicity of
peripheral circulation is associated with premenstrual
symptomatology.
Methods
Measurement principle and function of Astrim
Wavelengths in the near-infrared region are well absorbed
by blood, but they penetrate tissues. The Astrim portable
non-invasive monitoring device operates as follows: an
infrared or near-infrared light source (880, 805, and 660
nm) is positioned over the dorsal side of a finger, and a
CCD camera is positioned underneath the finger (Figure
2). The device provides an image of venous blood vessels
near the skin's surface on the finger. When the finger is
irradiated with light of differing wavelengths, the optical
density of the vascular portions of the images at the
respective wavelengths reflects the amount of light
absorbed by hemoglobin. In addition, direct measure-
ment of the vascular diameter of the optical image can
evaluate the amount of blood contributing to the light
absorption in the vascular portion of the image because
the blood vessel has a nearly circular cross section. Thus,
the blood hemoglobin content can be determined by the
amount of light absorption and the estimated amount of
blood.
The Astrim calculates venous blood vessel width and the
VOI based on the ratio of light absorption of HbO2 and
Hb. The VOI is calculated as the following equation: VOI
= -h2/h1. We define h1 and h2 as the degree of light
absorption of HbO2 and Hb at the wavelengths of 805
and 660 nm, respectively, in the near-infrared region. It
should be noted that HbO2 and Hb absorb light equally at
805 nm, whereas at 660 nm absorption is primarily from
Hb (Figure 3). The validity and reliability of the device has
been demonstrated in previous studies [7,8,11,12]. The
VOI has also been proven as an indicator in evaluating
peripheral venous oxygen metabolism and skin blood
flow under different physiological circumstances [6,9,10].
Subjects
Twenty-one young women (mean age, 20.6 ± 0.2 years)
volunteered to participate in this research. The study pro-
tocol was approved in advance by the Institutional Review
Board of International Buddhist University and was per-
formed in accordance with the Declaration of Helsinki.
All subjects received an explanation of the nature and pur-BioPsychoSocial Medicine 2007, 1:8 http://www.bpsmedicine.com/content/1/1/8
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pose of the study, and all gave their written informed con-
sent to participate in the study. Prior to obtaining any data
from experiments in the laboratory, the subjects com-
pleted a standardized health questionnaire regarding
medical history, medications, current health condition,
menstrual cycle (length of cycle, length of menstrual flow,
and regularity of cycle), premenstrual discomfort, diet,
physical activity, and lifestyle. All subjects self-reported
regular menstrual cycles for at least three cycles. None of
the subjects was clinically diagnosed with diabetes melli-
tus, hypertension, cardiovascular disease, or any other
endocrine or systemic disorders. The subjects were non-
obese (body mass index [BMI] < 25 kg/m2) and were not
taking any medications, including oral contraceptives.
Experimental Procedure
All subjects were examined on two separate occasions:
once during the follicular phase, within five days after the
completion of menstrual bleeding, and once during the
late luteal phase, within seven days before the next men-
struation. The order of testing was counterbalanced so
that equal numbers of subjects were studied first in each
phase. Cycle phase was determined by the onset of men-
struation and oral temperature and verified by concentra-
tions of ovarian hormones in a urine sample taken early
in the morning [13].
On the days of testing, subjects came to the laboratory
between 9:00 and 11:00 a.m. after having fasted over-
night. All experiments were performed in the morning.
The room was temperature controlled at 25°C, quiet and
comfortable, with minimization of arousal stimuli. After
weighing each subject, the percentage of body fat was
determined by means of a bioelectrical impedance ana-
lyzer (TBF-305, TANITA, Japan). BMI was calculated as
body weight divided by height squared.
The subjects rested for 10 minutes at room temperature
while seated in a comfortable chair. The left middle finger
was then placed on the detection probe of the device, and
hemoglobin levels, venous blood vessel width, and VOI
were automatically determined. The surface-skin temper-
ature of the finger was also measured by Digital Ther-
mometer (Tx10, YOKOKAWA). Each subject underwent
five trials at 30-second intervals. During the experiment,
the finger remained in the same position on the detection
probe.
After the subjects completed the experiment for peripheral
blood circulation, each filled out the Menstrual Distress
Questionnaire (MDQ) [14] which evaluated physical,
emotional, and behavioral symptoms accompanying the
menstrual cycle. The MDQ consists of 46 symptoms in
eight categories: pain, concentration, behavioral change,
autonomic reactions, water retention, negative affect,
arousal, and control. The MDQ has been widely used in
menstrual cycle research [13,15], and a recent study has
reconfirmed the validity and applicability of the question-
naire for evaluating menstrual symptoms [16].
Urinary analysis
Each subject collected urine at the first urine void in the
morning. Refrigerated 10-mL aliquots of urine were
immediately frozen and stored at -20°C until assay. Urine
samples were then analyzed for estrone conjugate (E1C)
and pregnanediol-3-glucuronide (PdG) by radioimmu-
noassay as described by Munro et al. [17] and De Souza et
al. [18]. E1C and PdG were both indexed to creatinine
(Cr) excretion in the same sample to control for variations
in urine volume. E1C and PdG are expressed as nano-
grams and micrograms per mg Cr, respectively.
Statistical analyses
All data are expressed as mean ± SE. Paired t-test was per-
formed to assess statistical differences of variables between
Definition of premenstrual disorders described in Chapter  61 of Shang han lun – the oldest Chinese practical textbook  of medicine – in the early third century Figure 1
Definition of premenstrual disorders described in Chapter 
61 of Shang han lun – the oldest Chinese practical textbook 
of medicine – in the early third century.
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the follicular and the late luteal phases. A comparison
between two groups was made with Student's unpaired t-
test. P values < 0.05 were considered statistically significant.
All statistical analysis was performed using a commercial
software package (SPSS version 13.0 for Windows, SPSS inc.,
Illinois).
Results
Clinical characteristics of subjects
The length of the menstrual cycle and the duration of
menstrual flow of all subjects during the study were 27.9
± 0.7 days and 6.1 ± 0.2 days, respectively. The days of the
experiments were 10.6 ± 0.3th day in the follicular phase
and 25.3 ± 0.7th day in the late luteal phase from the first
day of menstruation.
Concerning menstrual cycle symptomatology, some sub-
jects had apparent physical and psychological discomfort
in the late luteal phase while others experienced few
symptoms. To scrutinize the potential influence of pre-
menstrual discomfort on the peripheral circulation, we
divided the subjects into two groups based on the increase
in scores on the MDQ while referring to the findings from
our recent study [13], i.e., 11 subjects in the Control
Group (less than one point) and 10 subjects in the pre-
menstrual symptoms (PMS) Group (greater than 14
points). It should be mentioned, that according to the
results of a standardized health questionnaire and indi-
vidual interviews, none of the subjects in the PMS Group
experienced distressing physical, psychological, and/or
behavioral changes of sufficient severity to result in dete-
rioration of interpersonal relationships and/or interfer-
ence with normal activities. In addition, no subjects in the
present study sought medical treatment.
Table 1 shows clinical characteristics of the Control and
PMS Groups. Basal body temperature (p < 0.05) and con-
centration of E1C (p < 0.05) and PdG (p < 0.01) in urine
were more elevated in the late luteal phase than in the fol-
licular phase in both groups. Body weight (p < 0.01) and
BMI (p < 0.01) significantly increased in the late luteal
phase compared to the follicular phase only in the PMS
Group. Group comparison revealed no significant differ-
ence in ovarian hormones or in body composition during
the menstrual cycle between the Control and PMS
Groups.
Bio-psycho-behavioral symptoms
Figure 4 represents MDQ scores in the follicular and the
late luteal phases in the Control and PMS Groups. No sig-
nificant increase was detected either in subscores or in
total scores between the menstrual phases in the Control
Group. In the PMS Group, however, total scores markedly
increased from the follicular to the late luteal phase (p <
0.01). Scores of all factors were greater in the late luteal
phase than those in the follicular phase and significant
changes were detected in the following factors: pain (p <
0.05), concentration (p < 0.01), behavioral change (p <
0.05), water retention (p  < 0.05), negative affect (p  <
0.01), and control (p < 0.01).
Group comparison revealed no significant differences in
subscores or in total scores on the MDQ between the Con-
trol and PMS Groups in the follicular phase. The total
scores on the MDQ in the late luteal phase were, however,
significantly greater in the PMS Group than in the Control
Group. All subscores of the late luteal phase were higher
in the PMS Group compared to those in the Control
group, and statistical analysis further demonstrated signif-
icant differences in pain (p < 0.05), concentration (p <
0.01), behavioral change (p < 0.01), water retention (p <
0.01), negative affect (p < 0.01), and control (p < 0.01) fac-
tors.
Measurement principle of the Astrim Figure 2
Measurement principle of the Astrim. LED (light-emitting 
diode), CCD (charge-coupled device).
LED
Blood vessel
Optical System
CCD cameraBioPsychoSocial Medicine 2007, 1:8 http://www.bpsmedicine.com/content/1/1/8
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Peripheral circulation
According to our previous study investigating the validity
and reliability of the Astrim [9], data of each parameter
obtained from five trials were averaged for statistical anal-
ysis. No significant difference in hemoglobin levels was
found between the follicular and the late luteal phase in
the Control Group (11.8 ± 0.5 vs. 11.9 ± 0.4 g/dl). In the
PMS Group, hemoglobin levels were lower in the late
luteal phase compared to the follicular phase (12.1 ± 0.5
vs. 11.6 ± 0.9 g/dl) without statistically significant differ-
ences. The surface-skin temperature did not differ
between the menstrual phases in the Control Group (31.8
± 1.1 vs. 31.2 ± 0.4°C). No significant effect of the men-
strual cycle was found in the PMS Group (32.3 ± 0.6 vs.
31.2 ± 1.0°C) although the temperature was lower in the
late luteal phase.
As to the parameters of peripheral blood circulation
detected by the Astrim (Figure 5), no significant change
was found in the venous blood vessel width between the
menstrual phases in the Control Group. The width was
smaller in the late luteal phase compared to the follicular
phase in the PMS Group, but the difference did not reach
statistical significance. VOI decreased in the late luteal
phase in both groups. The degree of change in VOI from
the follicular to the late luteal phase was more apparent in
the PMS Group and the statistical analysis verified the sig-
nificant difference between the two phases (p < 0.05).
Discussion
Premenstrual syndrome has been recognized worldwide.
According to epidemiological reports, including ones in
Japan, approximately 70 to 90 percent of women of child-
bearing age experience at least some uncomfortable pre-
menstrual symptomatology, with from 2 to 10 percent
Physiological features of oxyhemoglobin (HbO2) and deoxyhemoglobin (Hb) represented by a thick red line and a dotted blue  line, respectively, in light absorption Figure 3
Physiological features of oxyhemoglobin (HbO2) and deoxyhemoglobin (Hb) represented by a thick red line and a dotted blue 
line, respectively, in light absorption. h1 and h2 represent the degree of light absorption of HbO2 and Hb at the wavelengths of 
805 and 660 nm, respectively, in the near-infrared region.
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having disabling, incapacitating symptoms [2,19].
Despite its high prevalence, no specific symptoms or signs
appear, nor are any recognizable anatomical factors iden-
tified in women suffering from premenstrual syndrome.
This leads to difficulty in appropriately diagnosing the
pathophysiological conditions and/or of offering effective
medical treatments.
From the perspective of traditional Chinese medicine,
now called Kampo Medicine, oketsu (blood stagnation)
and suidoku (disorders of water metabolism) have been
considered main factors in premenstrual syndrome. In
addition, premenstrual dysphoric disorder (PMDD), the
most severe type of premenstrual symptomatology, could
be attributable to inadequate blood flow induced by
oketsu, which results in qi stagnation including diverse
psychosomatic symptoms, i.e., pain, oppression in the
chest, abdominal distention, melancholia, depressive
mood, heavy feeling of the head, difficulty in breathing,
sensation of swelling, and stiffness in the extremities
[4,20,21]. Clinical studies have shown that tokaku-joki-to
(tao-he-cheng-qi-tang), a type of Kampo medicine for
overcoming blood stagnation, was a first-line therapy to
treat premenstrual discomfort, and kami-shoyo-san (jia-
wei-xiao-yao-san), keishi-buku-ryogan (gui-zhi-fu-ling-
wan), and toki-shakuyaku-san (dang-gui-shao-yao-san),
the typical herbal preparations improving blood circula-
tion, were also effective in alleviating and ameliorating
unidentified symptoms in the premenstrual phase [4,20].
These findings suggest that a deteriorated blood circula-
tory system could be associated with premenstrual symp-
tomatology; however, little substantial evidence has been
reported thus far.
In the present study, we used the VOI, a parameter
detected from the non-invasive monitoring devise with
optical technology, to investigate a potential etiologic
association between the peripheral circulation and pre-
menstrual symptomatology. As to the physiological sig-
nificance and features of VOI, a study at the Central
Research Laboratory of the Sysmex Corporation reported
a highly significant positive correlation between venous
oxygen saturation and the VOI [9]. Ozawa et al. [10] have
shown that the VOI as well as blood flow evaluated by the
laser Doppler blood-flowmeter dramatically decreased
against cold exposure. In addition, recent research [6,9]
has reported that the VOI markedly decreased during the
brachial 150 mmHg occlusion shortly after the handgrip
exercise. After releasing the occlusion, however, VOI
increased and returned to its level prior to the handgrip
exercise due to the restoration of blood circulation, which
contributed to improving oxygen supply. These findings
indicated that the VOI serves as an effective indicator of
peripheral venous oxygen metabolism and skin blood
flow under different physiological circumstances.
By applying the parameter to the present research, we have
found VOI decreased more significantly in the late luteal
phase than in the follicular phase only in the PMS Group.
In addition, the women of this group tend to possess
lower VOI in the late luteal phase than the Control Group.
It should be restated that scores of premenstrual symp-
toms were markedly higher in the PMS Group than in the
Control Group, but the symptoms were not as severe as to
cause disruption of daily activities or to need medical con-
sultations, according to the questionnaires and individual
interviews. It would be of interest to scrutinize whether
the VOI would markedly worsen in women suffering from
distressing and unbearable premenstrual symptoms
including PMDD when compared to healthy women
without symptoms.
Fluctuations in the ovarian hormones along the men-
strual cycle have been suggested to influence vasoconstric-
tion in peripheral blood vessels [22]. The present
investigation, however, detected no significant differences
in ovarian hormone concentration in either the follicular
or late luteal phase between the two groups. Simpson [23]
formally hypothesized that capillaries could be smaller in
size in women with premenstrual syndrome than asymp-
tomatic controls due to the altered noradrenergic and/or
thyroid functions. Girdler et al. [24] have revealed that
Table 1: Clinical characteristics of subjects in the follicular and late luteal phase
Control Group (n = 10) PMS Group (n = 11)
Follicular Luteal Follicular Luteal
Basal body temperature (°C) 36.04 ± 0.10 36.51 ± 0.14* 36.36 ± 0.08 36.43 ± 0.11*
Estrone conjugates (ng/ml Cr) 11.1 ± 2.3 20.4 ± 4.2* 12.6 ± 1.5 19.6 ± 6.2*
Pregnanediol-3-glucuronide (μg/ml Cr) 0.6 ± 0.2 3.7 ± 0.6** 0.4 ± 0.04 2.1 ± 0.4**
Weight (kg) 52.3 ± 1.7 52.5 ± 1.8 53.9 ± 1.8 54.6 ± 1.8**
Body Mass Index (kg/m2) 20.4 ± 0.4 20.4 ± 0.5 20.2 ± 0.6 20.5 ± 0.6**
Body fat (%) 25.9 ± 1.0 25.8 ± 1.0 24.8 ± 1.1 25.2 ± 1.1
Cr: creatinine
Values are means ± SE. **p < 0.01; *p < 0.05 (Follicular phase vs. Late luteal phase)BioPsychoSocial Medicine 2007, 1:8 http://www.bpsmedicine.com/content/1/1/8
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women with PMDD had significantly elevated norepine-
phrine and total peripheral resistance, which could affect
peripheral blood circulation, at rest and during mental
stressors compared with control subjects. Future research
will be needed to explicate exact neurophysiological and/
or hormonal effects of the menstrual cycle. The present
study, however, indicates that peripheral blood circula-
tion decreased in the symptomatic late luteal phase from
the non-symptomatic follicular phase even in eumenor-
rheic young women who were not diagnosed as having
serious premenstrual disorders, but experienced a sub-
stantial increase in diverse psychosomatic symptoms pre-
menstrually.
Conclusion
Premenstrual disorders can affect a woman at any stage in
her reproductive life – beginning around age 14, or about
2 years after menarche, and persist until around age 51,
when menopause typically occurs [25]. In this stage of
life, a woman's living environment as well as physiologi-
cal conditions can change dramatically. Several theories
have tried to explain the etiopathogenesis of premenstrual
syndrome [2,4,5], but the underlying biomechanisms
with the complex web of bio-psycho-socio-ethical factors
remain enigmatic. Although causes and consequences
continue to elude, the present study provides additional
intriguing evidence that the occurrence of premenstrual
symptomatology is associated with an altered functioning
of peripheral circulatory system in the late luteal phase.
This study has also shown the applicability of the non-
invasive monitoring devise using the principle of near-
infrared spectroscopy. Since it is non-invasive and
imposes no burden or pain during an examination, the
device could be utilized in diverse psycho-physiological
research and clinical situations, such as monitoring
patients' conditions and promoting women's health.
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Comparison of scores on the menstrual distress questionnaire (MDQ) between the follicular and late luteal phases in the Con- trol and PMS Groups Figure 4
Comparison of scores on the menstrual distress questionnaire (MDQ) between the follicular and late luteal phases in the Con-
trol and PMS Groups. Results are expressed as mean ± SE. for each group. ** p < 0.01; * p < 0.05.
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